Monopar Therapeutics MNPR Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -14.2%+37.2pp | -51.4%+55.8pp | -107.2%-34.7pp | -72.4%-19.9pp | |
| Efficiency | |||||
| Asset turnover | 0×— | 0×— | 0×— | —— | |
| Liquidity | |||||
| Current ratio | 51.4×+39.9× | 11.5×+7.3× | 4.2×0.0× | 4.2×-8.8× | |
| Leverage | |||||
| Debt-to-equity | 0×— | —— | 0×0.0× | 0×— | |
| Valuation | |||||
| Market capitalization | $587.04M+192% | $134.17M+2,553% | $5.06M-83.5% | $30.62M-24.2% | |
| Price / book | 4.3×+0.6× | 2.4×+1.5× | 0.9×-2.1× | 3×+0.9× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Monopar Therapeutics's ratios come from?
- Every ratio is computed from Monopar Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.